We demonstrated that PSPC1 inhibition enhanced olaparib efficacy in a preclinical model of breast or ovarian cancer with BRCA1/2 mutations compared to olaparib alone, suggesting a promising therapeutic alternative to enhancing PARP inhibitor sensitivity in non-resistance settings. Here, BRCA1 is linked to ovarian carcinoma.